Its losses have been rising in recent years as has its share count -- a notable concern for investors. 10 stocks we like ...

They hunt in a nightmarish way ― grabbing prey as it passes. Once secured with a bite, pythons wrap their bodies around their ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Gov. Ron DeSantis announced a new partnership with a Miami-based company to help remove more invasive Burmese pythons from the Everglades, where they have decimated native species for years.

Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. This article is more than 5 years old. Chris Gibson, Co-Founder & CEO, Recursion ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...